Image de couverture de livre

CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Hye Won Lee, Terry Cheuk‐Fung Yip, Vincent Wai‐Sun Wong, Young‐Suk Lim, Henry Lik‐Yuen Chan, Sang Hoon Ahn, Grace Lai‐Hung Wong, Jonggi Choi
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients
par: Jian Wang, et autres
Publié: (2024)

Higher end‐of‐treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg‐negative chronic hepatitis B patients stopping antivirals
par: Yen‐Chun Liu, et autres
Publié: (2024)

Dynamics of Circulatory HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation Using iTACT Assays to Predict Clinical Flares and HBsAg Loss
par: Ying‐Nan Tsai, et autres
Publié: (2026)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
par: Hyeyeon Hong, et autres
Publié: (2024)

Virological and Immunological Characteristics of HBeAg ‐Positive Chronic Hepatitis B Patients With Low HBsAg Levels
par: Yuxin Chen, et autres
Publié: (2024)

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B—Authors' Reply
par: Jian Wang, et autres
Publié: (2025)

Editorial: Polypharmacy in MASLD—An Overlooked Epidemic Disproportionately Affecting Women and Patients With Cirrhosis
par: Mary Yue Wang, et autres
Publié: (2025)

Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate
par: Wen‐Juei Jeng, et autres
Publié: (2025)

Editorial: Using HBcrAg and HBsAg Kinetics to Optimise Monitoring After Nucleo(s)tide Analogue Withdrawal
par: Edo J. Dongelmans, et autres
Publié: (2026)

Favourable Prognosis of Patients With Untreated HBeAg‐Negative Chronic Hepatitis B Virus Infection With HBsAg < 100 IU/mL
par: Jian Wang, et autres
Publié: (2024)

Editorial: HBeAg ‐Positive Chronic Hepatitis B With Low HBsAg Levels—Exploring Clinical Significance of preS2 Deletion Mutations
par: Ying‐Nan Tsai, et autres
Publié: (2025)

Letter: Dynamic HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation: Considerations in Interpreting Predictive Performance
par: Hsiang‐Ting Keng, et autres
Publié: (2026)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance. Authors' Reply
par: Terry Cheuk‐Fung Yip, et autres
Publié: (2025)

Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate—Authors' Reply
par: Ying‐Nan Tsai, et autres
Publié: (2025)

Editorial: HBeAg ‐Positive Chronic Hepatitis B With Low HBsAg Levels—Exploring Clinical Significance of preS2 Deletion Mutations. Authors' Reply
par: Yuxin Chen, et autres
Publié: (2025)

Editorial: Using HBcrAg and HBsAg Kinetics to Optimise Monitoring After Nucleo(s)tide Analogue Withdrawal. Authors' Reply
par: Yasuhito Tanaka, et autres
Publié: (2026)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation. Authors' Reply
par: Mary Yue Wang, et autres
Publié: (2026)

Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC
par: Xiaosong Li, et autres
Publié: (2024)

Long‐Term Follow‐Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss
par: Simon J. Hume, et autres
Publié: (2025)

Letter: Antiviral Prophylaxis Mitigates HBV Reactivation Risk During Cancer Immunotherapy: Unresolved Challenges and Future Directions—Authors' Reply
par: Landon Long Chan, et autres
Publié: (2025)

Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC
par: Naohiro Yasuura, et autres
Publié: (2024)

Serum sPD‐1 and sPD‐L1 as predictive biomarkers for HBsAg clearance in HBeAg‐negative CHB patients undergoing IFN‐based therapy
par: Xiyao Chen, et autres
Publié: (2024)

Letter: Muddle of serum sPD‐1 and sPD‐L1 levels and association with HBsAg clearance in HBeAg‐negative CHB patients on IFN therapy
par: Ankur Jindal
Publié: (2024)

Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
par: Maria Buti, et autres
Publié: (2024)

Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply
par: Jonggi Choi
Publié: (2025)

Editorial: High qHBsAg—Is it a good or bad signal? Authors' reply
par: Hsin‐Che Lin, et autres
Publié: (2024)

Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes
par: Xianhua Mao, et autres
Publié: (2024)

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
par: Sung Won Chung, et autres
Publié: (2024)

Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments
par: Chen‐Pi Li, et autres
Publié: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B
par: Jian Wang, et autres
Publié: (2024)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy
par: Yu Jun Wong
Publié: (2025)

Letter: Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in chronic hepatitis B virus infection
par: Jianrong Li, et autres
Publié: (2024)

Evaluation of Factors Influencing Specialist Referral Among Individuals Tested Positive for HBsAg in Health Check Programs in Hong Kong
par: Henry Lik Yuen Chan, et autres
Publié: (2025)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B
par: Jing Li, et autres
Publié: (2024)

Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in patients with normal ALT in the grey zone of chronic hepatitis B virus infection
par: Na‐Ling Kang, et autres
Publié: (2024)

Letters on “Efficacy and Safety of Tenofovir Alafenamide ( TAF ) and Tenofovir Disoproxil Fumarate ( TDF ) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment.” Authors' Reply
par: Grace Lai‐Hung Wong, et autres
Publié: (2025)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B ‐ authors' reply
par: WenXian OuYang, et autres
Publié: (2024)

Meta‐Analysis: High anti‐ HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment
par: Shiva Poola, et autres
Publié: (2025)

Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment
par: Grace Lai‐Hung Wong, et autres
Publié: (2025)

Racial and ethnic disparities in untreated patients with hepatitis C virus‐related hepatocellular carcinoma but not in those with sustained virologic response
par: Jung Eun Park, et autres
Publié: (2024)